In-particle design®: new mSAS® solutions to solubility challenge
Dr Lyn Daintree
Crystec Pharma
UK

Dr Lyn Daintree gained her doctorate from the School of Pharmacy at the University of Bradford whilst working for Bradford Particle Design. She subsequently led a team developing new products for Nektar Therapeutics. Dr Lyn Daintree has extensive knowledge of formulation development using supercritical fluids. Her SCF processing experience includes developing methods to control particle size and surface area, chiral separation, polymorph control and generation of stable composite systems. Dr Daintree is currently working at Crystec Pharma as Development Director where she is responsible for scientific programme management for external client projects, proprietary molecules, compliance, new opportunity assessment and development of intellectual property. Dr Daintree, may I please welcome you to present you talk on In-particle design®: new mSAS® solutions to solubility challenge.

An event organised by the Royal Society of Chemistry's Formulation Science & Technology (FST) Interest Group.